Journal article

Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials

Wei Zheng, Xian-Bin Li, Zhan-Ming Shi, Xin-Hu Yang, Dong-Bin Cai, Chee H Ng, Gabor S Ungvari, Wei-Jian Liu, Yu-Jie Wu, Yuan-Yuan Wang, Yu-Ping Ning, Yu-Tao Xiang

PHARMACOPSYCHIATRY | GEORG THIEME VERLAG KG | Published : 2020

Abstract

BACKGROUND: Results of previous studies on the safety and efficacy of adjunctive reboxetine for schizophrenia have been inconsistent. AIM: The aim of this study was to examine the efficacy and tolerability of reboxetine as an adjunct medication to antipsychotic treatment in a meta-analysis of randomized controlled trials (RCTs). METHODS: Two independent investigators extracted data for a random effects meta-analysis and assessed the quality of studies using risk of bias and the Jadad scale. Weighted and standardized mean differences (WMDs/SMDs) and risk ratio (RR)±95% confidence intervals (CIs) were calculated. RESULTS: Nine RCTs (n=630) with double-blind design were identified. Reboxetine o..

View full abstract

University of Melbourne Researchers

Grants

Awarded by University of Macau


Awarded by National Natural Science Foundation of China


Awarded by Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support


Awarded by Capital's Funds for Health Improvement and Research


Awarded by Major Science and Technology Award of the Science and Technology Department of Guangdong Province


Funding Acknowledgements

The study was supported by the University of Macau (SRG2014-00019-FHS; MYRG2015-00230-FHS; MYRG2016-00005-FHS), the National Natural Science Foundation of China (81601169), the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201807, XLMX201807), Capital's Funds for Health Improvement and Research (2018-2-2123), and the Major Science and Technology Award of the Science and Technology Department of Guangdong Province (2016B0 10108003).